军事知识服务平台
肿瘤供血动脉灌注化疗栓塞联合射频消融治疗晚期非小细胞肺癌的疗效分析
Efficacy for artery chemoembolization combined with radiofrequency ablation in the treatment of advanced non-small cell lung cancer
摘要 目的:探讨肿瘤供血动脉灌注化疗栓塞联合射频消融治疗晚期非小细胞肺癌( NSCLC)的临床疗效及安全性。方法回顾性分析四川省肿瘤医院2011年1月—2014年11月介入治疗的138例晚期NSCLC患者的临床资料,其中肿瘤供血动脉灌注化疗栓塞组(灌注组)61例,肿瘤供血动脉灌注化疗栓塞联合射频消融治疗组(联合组)43例,射频消融治疗组(射频组)34例。统计分析3组患者的近期有效率、生存时间、不良反应、并发症以及影响3组患者生存时间的相关危险因素。结果灌注组、联合组、射频组的近期有效率分别为73.8%(45/61)、93.0%(40/43)、85.3%(29/34),差异有统计学意义(χ2=18.499,P=0.005)。联合组1、2、3年生存率分别为90.7%(39/43)、58.1%(25/43)、20.9%(9/43)好于灌注组的57.4%(35/61)、24.6%(15/61)、11.5%(7/61)和射频组的58.8%(20/34)、32.4%(11/34)、11.8%(4/34),(χ2值分别为8.242和4.934,P值分别为0.004和0.026)。化疗不良反应及消融并发症差异均无统计学意义(均P>0.05)。肿瘤数量、肿瘤直径、TNM分期、美国东部肿瘤协作组( ECOG)评分是影响患者生存时间的独立危险因素,肿瘤供血动脉灌注化疗栓塞联合射频消融治疗可改善晚期NSCLC患者生存时间。结论肿瘤供血动脉灌注化疗栓塞联合射频消融治疗晚期NSCLC是一种安全、有效、微创的治疗方法。
Abstract:
Objective To investigate efficacy and safety of artery chemoembolization combined with radiofrequency ablation for advanced non-small cell lung cancer.Methods A total of 138 cases of Sichuan Cancer Hospital of patients with advanced non-small cell lung cancer were retrospectively analyzed from January 2011 to November 2014.All cases were divided into three groups, 61 cases were treated by artery chemoembolization ( ACB group ) , 43 cases were treated by artery chemoembolization combined with radiofrequency ablation ( Joint group), 34 cases were treated by radiofrequency ablation (RFA group). Recent efficiency, overall survival time, adverse reactions and complications of three groups were analyzed. The risk factors related to survival time of 138 patients were analyzed.Results The recent efficiency of ACB group, Joint group and RFA group were 73.8%(45/61),93.0%(40/43),85.3%(29/34), respectively, and the difference was statistically significant (χ2 =18.499, P=0.005).1, 2, 3-year survival rates of Joint group were 90.7%(39/43),58.1%(25/43),20.9%(9/43), respectively that were better than ACB group(57.4%(35/61),24.6%(15/61),11.5%(7/61)) and RFA group(58.8%(20/34),32.4%(11/34),11.8%(4/34)), (χ2 value were respectively 8.242 and 4.934, P values were 0.004 and 0.026). Chemotherapy side effects and complications of ablation were of no significant difference (P>0.05). Chemotherapy side effects and complications of ablation were of no significant difference ( P>0.05 ) .The number of tumors, tumor size, TNM staging, eastern cooperative oncology group ( ECOG ) score were independent risk factors which impact on survival time for non-small cell lung cancer.The artery chemoembolization combined with radiofrequency ablation treatment can improve survival time of patients with advanced non-small cell lung cancer.Conclusion Artery chemoembolization combined with radiofrequency ablation is a safe, effective, minimally-invasive treatment for advanced non-small cell lung cancer.
Author: Yang Xuegang Wu Ge Li Zhengwen Wu Hui Sun Yanyuan Wen Huachang Xu Guohui
作者单位: 四川省肿瘤医院介入科, 成都,610041
刊 名 中华医学杂志 ISTICPKU
年,卷(期): 2016, (7)
机标分类号: R73 R97
在线出版日期: 2016年4月14日